Cambium Bio (ASX:CMB) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cambium Bio's Revenue for the six months ended in Dec. 2024 was A$0.00 Mil. Cambium Bio's average Accounts Receivable for the six months ended in Dec. 2024 was A$0.22 Mil.

Cambium Bio Receivables Turnover Historical Data

The historical data trend for Cambium Bio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Receivables Turnover Chart

Cambium Bio Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Receivables Turnover

Get a 7-Day Free Trial

Cambium Bio Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Receivables Turnover

For the Biotechnology subindustry, Cambium Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Cambium Bio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Cambium Bio's Receivables Turnover for the fiscal year that ended in Jun. 2024 is calculated as

	Receivables Turnover (A: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2024 )	/ (	(Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )
=	0.001	/ (	(0	+	0.257)	/	1 )
=	0.001	/	0.257
=	0.00

Cambium Bio's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Jun. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0.257	+	0.19)	/	2 )
=	0	/	0.2235
=	N/A

Cambium Bio (ASX:CMB) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Cambium Bio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.cambium.bio

Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines